CA2335112A1 - Therapeutic combinations for musculoskeletal frailty - Google Patents

Therapeutic combinations for musculoskeletal frailty Download PDF

Info

Publication number
CA2335112A1
CA2335112A1 CA002335112A CA2335112A CA2335112A1 CA 2335112 A1 CA2335112 A1 CA 2335112A1 CA 002335112 A CA002335112 A CA 002335112A CA 2335112 A CA2335112 A CA 2335112A CA 2335112 A1 CA2335112 A1 CA 2335112A1
Authority
CA
Canada
Prior art keywords
compound
oxo
ethyl
pyridin
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002335112A
Other languages
English (en)
French (fr)
Inventor
Hua Zhu Ke
David Duane Thompson
Mei Li
Lydia Codetta Pan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2335112A1 publication Critical patent/CA2335112A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002335112A 1998-06-16 1999-05-03 Therapeutic combinations for musculoskeletal frailty Abandoned CA2335112A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8942498P 1998-06-16 1998-06-16
US60/089,424 1998-06-16
PCT/IB1999/000796 WO1999065488A1 (en) 1998-06-16 1999-05-03 Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty

Publications (1)

Publication Number Publication Date
CA2335112A1 true CA2335112A1 (en) 1999-12-23

Family

ID=22217565

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002335112A Abandoned CA2335112A1 (en) 1998-06-16 1999-05-03 Therapeutic combinations for musculoskeletal frailty

Country Status (29)

Country Link
EP (1) EP1085867A1 (zh)
JP (1) JP2002518328A (zh)
KR (1) KR20010052817A (zh)
CN (1) CN1305378A (zh)
AP (1) AP9901581A0 (zh)
AR (1) AR018868A1 (zh)
AU (1) AU3342099A (zh)
BG (1) BG105128A (zh)
BR (1) BR9911357A (zh)
CA (1) CA2335112A1 (zh)
CO (1) CO5070586A1 (zh)
EA (1) EA200001189A1 (zh)
GT (1) GT199900083A (zh)
HR (1) HRP20000857A2 (zh)
HU (1) HUP0102395A2 (zh)
ID (1) ID26726A (zh)
IL (1) IL139587A0 (zh)
IS (1) IS5727A (zh)
MA (1) MA26648A1 (zh)
NO (1) NO20006381L (zh)
OA (1) OA11569A (zh)
PA (1) PA8472101A1 (zh)
PE (1) PE20000633A1 (zh)
PL (1) PL345064A1 (zh)
SK (1) SK18902000A3 (zh)
TN (1) TNSN99118A1 (zh)
UY (1) UY25557A1 (zh)
WO (1) WO1999065488A1 (zh)
ZA (1) ZA993973B (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1004306A3 (en) * 1998-08-06 2000-06-07 Pfizer Products Inc. Estrogen agonists/antagonists
JP2004507502A (ja) 2000-08-30 2004-03-11 ファイザー・プロダクツ・インク 成長ホルモン分泌促進物質のための徐放性製剤
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
US7524866B2 (en) 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
EP1666033B1 (en) * 2001-11-29 2008-12-31 GTX, Inc. Prevention and treatment of androgen-deprivation induced osteoporosis
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
JP2010518090A (ja) 2007-02-09 2010-05-27 トランザイム・ファーマ，インコーポレイテッド 大環状グレリン受容体修飾因子およびその使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA51676C2 (uk) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis

Also Published As

Publication number Publication date
ID26726A (id) 2001-02-01
PL345064A1 (en) 2001-11-19
EP1085867A1 (en) 2001-03-28
TNSN99118A1 (fr) 2005-11-10
IL139587A0 (en) 2002-02-10
NO20006381D0 (no) 2000-12-14
GT199900083A (es) 2000-12-05
AU3342099A (en) 2000-01-05
WO1999065488A1 (en) 1999-12-23
SK18902000A3 (sk) 2001-12-03
BG105128A (en) 2001-11-30
HUP0102395A2 (hu) 2001-11-28
EA200001189A1 (ru) 2001-06-25
MA26648A1 (fr) 2004-12-20
JP2002518328A (ja) 2002-06-25
AR018868A1 (es) 2001-12-12
KR20010052817A (ko) 2001-06-25
ZA993973B (en) 2000-12-15
CO5070586A1 (es) 2001-08-28
OA11569A (en) 2004-07-01
CN1305378A (zh) 2001-07-25
BR9911357A (pt) 2001-03-13
HRP20000857A2 (en) 2001-10-31
AP9901581A0 (en) 1999-06-30
IS5727A (is) 2000-11-24
PE20000633A1 (es) 2000-07-26
UY25557A1 (es) 2001-01-31
PA8472101A1 (es) 2000-09-29
NO20006381L (no) 2000-12-14

Similar Documents

Publication Publication Date Title
ES2312169T3 (es) Terapia combinada para osteoporosis.
US7632813B2 (en) Bone densifying agent characterized by use of cathepsin K inhibitor with PTH
PT1414486E (pt) Utilizaã†o de glp-2 em combinaã†o com outro agente terap—utico em perturbaãŽes ësseas
US20040122062A1 (en) Use of growth hormone secretagogues for treatment of physical performance decline
CA2335112A1 (en) Therapeutic combinations for musculoskeletal frailty
OA11566A (en) Therapeutic combinations comprising a selective estrogen receptor modulator and parathyroid hormone.
AU4054799A (en) Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty
US20020002137A1 (en) Combination of growth hormone secretagogues and antidepressants
AU7613001A (en) Use of growth hormone secretagogues in conjunction with physical exercise
MXPA00012628A (en) Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty
CA2274381C (en) Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin e2
JP2002293743A (ja) 食欲を刺激するかまたは増進させるための成長ホルモン分泌促進物質の使用
CZ20004680A3 (cs) Terapeutické kombinace (selektivních) modulátorů estrogenního receptorů (ŠERM) a prostředků podporujících sekreci růstového hormonu (GHS) pro léčbu muskuloskeletární fragility
MXPA00012727A (en) Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty
US20030199514A1 (en) Methods for improving efficacy of treatment with growth hormone secretagogues
CZ20004679A3 (cs) Terapeutické kombinace (selektivních) modulátorů estrogenního receptoru (ŠERM) a prostředků podporujících sekreci růstového hormonu (GHS) pro léčbu muskuloskeletární fragility
MXPA00012728A (en) Therapeutic combinations comprising a selective estrogen receptor modulator and parathyroid hormone
MXPA99005564A (en) Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin e2
AU2463301A (en) Weight promoting composition, method, and product

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued